Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 9/20 | 0.77 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.77 |
| ▸ | HTR1A | P08908 | 1/20 | 0.77 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.77 |
| ▸ | DRD3 | P35462 | 1/20 | 0.77 |
| ▸ | HTR2B | P41595 | 1/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.77 |
| ▸ | GALR3 | O60755 | 1/20 | 0.61 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2312870 | 0.90 | HCRTR2 (0.77) | HCRTR1HCRTR2HTR1AOPRM1DRD3 | |
| SCHEMBL3624130 | 0.87 | HCRTR1 (1.00) | HCRTR1HCRTR2HTR1AOPRM1DRD3 | |
| SCHEMBL2314409 | 0.85 | GALR3 (0.65) | HCRTR1HCRTR2HTR1AOPRM1DRD3 | |
| SCHEMBL2253441 | 0.84 | HCRTR2 (0.68) | HCRTR1HCRTR2HTR1AOPRM1DRD3 | |
| SCHEMBL3625355 | 0.83 | HCRTR1 (0.83) | HCRTR1HCRTR2HTR1AOPRM1DRD3 | |
| SCHEMBL3623216 | 0.83 | HCRTR1 (1.00) | HCRTR1HCRTR2HTR1AOPRM1DRD3 | |
| SCHEMBL3625065 | 0.82 | HCRTR1 (1.00) | HCRTR1HCRTR2HTR1AOPRM1DRD3 | |
| SCHEMBL2308080 | 0.81 | GALR3 (0.61) | HCRTR1HCRTR2HTR1AOPRM1DRD3 | |
| SCHEMBL14082550 | 0.79 | SMN1; SMN2 (0.77) | HCRTR1HCRTR2HTR1AOPRM1DRD3 | |
| SCHEMBL2250557 | 0.79 | HCRTR2 (0.75) | HCRTR1HCRTR2HTR1AOPRM1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2349262-B1 | 2,5-DISUBSTITUTED PHENYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-06-25 | — | — | EP | claimed |
| US-8399494-B2 | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | claimed |
| US-20110207747-A1 | 2,5-Disubstituted Phenyl Carboxamide Orexin Receptor Antagonists | MERCK & CO., INC. | 2011-08-25 | — | — | US | claimed |
| EP-2349262-A1 | 2,5-DISUBSTITUTED PHENYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2011-08-03 | — | — | EP | claimed |
| WO-2010051237-A1 | 2,5-DISUBSTITUTED PHENYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | claimed |
| EP-2349262-B1 | 2,5-DISUBSTITUTED PHENYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-06-25 | — | — | EP | disclosed |
| EP-2349262-B1 | 2,5-DISUBSTITUTED PHENYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8399494-B2 | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399494-B2 | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399494-B2 | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110207747-A1 | 2,5-Disubstituted Phenyl Carboxamide Orexin Receptor Antagonists | MERCK & CO., INC. | 2011-08-25 | — | — | US | disclosed |
| US-20110207747-A1 | 2,5-Disubstituted Phenyl Carboxamide Orexin Receptor Antagonists | MERCK & CO., INC. | 2011-08-25 | — | — | US | disclosed |
| US-20110207747-A1 | 2,5-Disubstituted Phenyl Carboxamide Orexin Receptor Antagonists | MERCK & CO., INC. | 2011-08-25 | — | — | US | disclosed |
| WO-2010051237-A1 | 2,5-DISUBSTITUTED PHENYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207747-A1 | 2,5-Disubstituted Phenyl Carboxamide Orexin Receptor Antagonists | HCRTR2, HCRTR1, CRHR2 | HCRTR1 2/4885HCRTR2 1/4885HTR1A 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.